Tandem Mobi Now Compatible with Android Smartphones

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery system,1 can now be used with compatible Android smartphones in the U.S. via the Tandem Mobi mobile app. "By expanding to Android, we're broadening our reach to bring the benefits of Tandem Mobi to even more people living with diabetes," said John Sheridan, president and chief.

Business Wire • Mar 4, 2026

Tandem Diabetes Care, Inc. (TNDM) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript

Tandem Diabetes Care, Inc. (TNDM) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript

Seeking Alpha • Feb 26, 2026

Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously a.

Business Wire • Feb 25, 2026

Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today that it intends to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of its Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “S.

Business Wire • Feb 23, 2026

Tandem Diabetes Care: Strong Q4 Execution Amid A PayGo Transition

Tandem Diabetes Care, Inc. delivered strong Q4 '25 results, with revenue and gross margin beats driving a 32% stock surge. TNDM's shift to a pay-as-you-go model will temporarily compress reported revenue but should enable smoother, recurring income and improved long-term economics.

Seeking Alpha • Feb 23, 2026

Tandem Diabetes Care Analysts Boost Their Forecasts After Upbeat Q4 Results

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) reported better-than-expected fourth-quarter financial results on Thursday.

Benzinga • Feb 20, 2026

Tandem Diabetes Shares Rise 33% On Earnings Beat, Margin Expansion, Growth Outlook

The stock is moving higher as the broader market is experiencing positive momentum, with the Nasdaq up 0.62% today, contributing to the bullish sentiment.

Benzinga • Feb 20, 2026

Why Tandem Diabetes Care Stock Popped Today

Tandem saw robust demand for its insulin pumps in the fourth quarter. Management expects further shipment growth in 2026.

The Motley Fool • Feb 21, 2026

Tandem Diabetes Care, Inc. (TNDM) Q4 2025 Earnings Call Transcript

Tandem Diabetes Care, Inc. (TNDM) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 20, 2026

TNDM Q4 Earnings & Revenues Beat Estimates, Gross Margin & Stock Up

Tandem Diabetes tops Q4 estimates with narrower loss, 15% revenue jump and wider gross margin, sending shares up 6.7% after hours.

Zacks Investment Research • Feb 20, 2026